Clinical Trial Update: Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SHR-A1921 in combination with Adebrelimab for advanced hormone-receptor-positive, HER2-negative breast cancer. The study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• SHR-A1921

Snippet

Sponsor: Fudan University | Conditions: Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING